Form 4: Viridian Therapeutics CEO Receives Significant Equity Awards

Viridian Therapeutics' President and CEO, Stephen F. Mahoney, reported the acquisition of substantial stock options and restricted stock units, alongside the vesting and tax-related disposition of common stock.

Summary

• Stephen F. Mahoney, President and CEO of Viridian Therapeutics, Inc. (VRDN), reported transactions involving the company's securities.
• Acquired 559,600 stock options with an exercise price of $30.25, granted on March 2, 2026, vesting in 48 equal monthly installments.
• Acquired 111,900 Restricted Stock Units (RSUs) on March 2, 2026, vesting over a four-year period with 25% vesting on each yearly anniversary.
• Acquired 18,357 shares of common stock on March 3, 2026, resulting from the vesting of previously granted RSUs.
• Disposed of 7,627 shares of common stock on March 3, 2026, at a price of $29.32 per share, to cover tax liabilities associated with RSU vesting.
• Beneficially owns 33,130 shares of common stock following these transactions, which includes 1,000 shares acquired under the 2016 Employee Stock Purchase Plan on March 17, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the significant equity awards align the CEO's financial interests with the company's long-term performance, which is generally favorable for shareholders. The tax-related sale is a standard, non-discretionary event.

Positives

• The President and CEO received significant equity awards (559,600 stock options and 111,900 RSUs), aligning management's interests with long-term shareholder value.
• The vesting schedules for both options and RSUs encourage continued service and performance over several years.

Negatives

• A portion of vested shares (7,627 shares) was disposed of to cover tax obligations, which is a standard practice but reduces the CEO's direct common stock holdings in the short term.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the granting of stock options and restricted stock units to executive leadership is a common practice in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align executive interests with shareholder returns. This type of compensation is standard for a company like Viridian Therapeutics, Inc. (VRDN) as it progresses through clinical development and commercialization efforts.

Comparison to Industry Standards

• The equity compensation package for Stephen F. Mahoney, including stock options and RSUs, is consistent with typical executive incentive structures observed in comparable biopharmaceutical companies of similar market capitalization and development stage.
• The vesting schedules (48 equal monthly installments for options, four-year annual vesting for RSUs) are standard for long-term incentive plans in the industry, promoting executive retention and sustained performance.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's incentives with shareholder value creation over the long term. The tax-related sale is a minor, non-discretionary event.
• Employees: The compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives.

Key Dates

Recommendation

The filing details routine executive compensation grants and a tax-related share disposition. These are standard corporate events and do not provide new fundamental information that would warrant a change in investment recommendation. Investors should 'hold' as these transactions are expected and do not signal a significant shift in company prospects or insider sentiment beyond standard compensation practices.

Keywords

Viridian Therapeutics, VRDN, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Equity Awards, Stephen F. Mahoney